577 / 1241
Identification of a MRI perfusion biomarker to anticipate
progression of glioblastoma after radio-chemotherapy
•
25 patients of spectro glio trial , follow up
> 6 months
•
Analysis of 11 perfusion biomarkers
•
The fraction of hypoperfused tumoral volume
≥
0.61 could anticipate relapse at the following scan
with sensibility/specificity of 92.3%/63.6%
•
In the group >0,61 , 75% relapses vs 12.5%, p = 0.008.
Khalifa et al, Eur J Radiology 2016